LobbyingAve Maria Biotech lobbying by quarter
Ave Maria Biotech's latest lobbying report covers Q4 2025, at under $5,000. Its first report covers Q1 2025; the issues it reports most are Defense.
Ave Maria Biotech
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q1 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2025 | $10K | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Defense$10K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES4 reports
- SENATE4 reports
Firms it paid
| Firm | ||
|---|---|---|
| Cross Potomac Consulting | $10K | 4 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 01/20for Q4 2025 | Cross Potomac Consulting | Under $5,000 |
| 25/10/18for Q3 2025 | Cross Potomac Consulting | Under $5,000 |
| 25/07/16for Q2 2025 | Cross Potomac Consulting | Under $5,000 |
| 25/04/19for Q1 2025 | Cross Potomac Consulting | $10K |
| 25/04/16for Q1 2025 | Cross Potomac Consulting | Under $5,000 |